The Isotope Production Map Q2 2026 is a 56-page, facility-level intelligence report mapping supply sufficiency, production capacity, and upstream fragility across all 38 radiopharmaceutical isotopes in clinical or commercial deployment - including reactor ageing timelines, precursor feedstock ceilings, the Ac-225 crisis window, correlated fragility clusters, and the three market mispricings the sector has not yet priced in. Built for isotope producers, radiopharmaceutical executives, investors, CDMO operators, and corporate development teams, it shows which announced capacity will actually arrive, which supply chains trace back to a single reactor, and where physics overrides capital.